Results 191 to 200 of about 72,056 (263)

Animal Naming Test Can Identify Covert Hepatic Encephalopathy in Patients With Cirrhosis With Limited Influence From Age or Educational Level

Hepatology Research, EarlyView.
Adjustments for age and educational level in animal naming test cause patients’ discomfort and limit its use in clinical practice. In our study, animal naming test was useful in identifying covert hepatic encephalopathy and its adjustment using age and educational level had limited incremental value the diagnostic ability.
Takao Miwa, Shinji Unome, Sachiyo Hirata, Satomi Nakashima, Kayoko Nishimura, Yoshiyuki Miwa, Teruo Maeda, Masashi Aiba, Masahito Shimizu   +8 more
wiley   +1 more source

Research advances on gut microbiota dysbiosis and chronic liver diseases: a review. [PDF]

Front Med (Lausanne)
Yang G, Zhu J, Wang M, She S, Dai K.
europepmc   +1 more source

Machine Learning Approach Enables Highly Accurate Identification of At‐Risk Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, EarlyView.
ABSTRACT Aim At‐risk metabolic dysfunction‐associated steatohepatitis (MASH), characterized by significant activity and fibrosis, increases the risk of liver complications. Liver stiffness measurement (LSM), commonly used to detect significant fibrosis, has limitations in terms of accessibility and performance in certain populations.
Masaya Sato, Takuma Nakatsuka, Tatsuya Minami, Yotaro Kudo, Rie Irie, Hanako Tsujikawa, Takumi Kawaguchi, Hirokazu Takahashi, Yuichiro Eguchi, Eisuke Murakami, Kazuaki Chayama, Takeshi Okanoue, Michiie Sakamoto, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi   +15 more
wiley   +1 more source

Predicting short-term mortality in severe cirrhosis: An interpretable machine learning model integrating routine clinical indicators. [PDF]

PLoS One
Zhang S, Liu R, Li Z, Pan T, Wen X.
europepmc   +1 more source

Interleukin 13 (IL-13) Signalling as a Potential Target for Cell Therapies in Liver Fibrosis. [PDF]

Int J Mol Sci
Mazurski A, Bednarz A, Czekaj P.
europepmc   +1 more source

Etiology, intervention duration, and standardization in sarcopenia management for liver cirrhosis: current challenges and future directions. [PDF]

Hepatobiliary Surg Nutr
Hsu HC, Lee HF.
europepmc   +1 more source

Case Report of a patient with Madelung's disease combined with alcoholic liver disease and liver cirrhosis. [PDF]

Front Med (Lausanne)
Gu Z, Hao Y, Duan J, Zhao K.
europepmc   +1 more source

Comparative analysis of autophagy and apoptosis pathways in viral and alcoholic cirrhosis: An immunohistochemical study. [PDF]

Saudi Med J
Demircan G, Berk S, Karayilan D, Ozgur BT, Ketenci S, Elbegi I, Karpuz V, Yavuz M, Midi A, Akin D.   +9 more
europepmc   +1 more source